ABVC ABVC BIOPHARMA, INC.

Nasdaq abvcpharma.com


$ 2.91 nm (nm)    

Friday, 17-Oct-2025 15:59:54 EDT
QQQ $ 604.85 $ 3.94 (0.66 %)
DIA $ 461.79 $ 2.22 (0.48 %)
SPY $ 665.04 $ 3.75 (0.57 %)
TLT $ 91.08 $ -0.14 (-0.15 %)
GLD $ 390.93 $ -7.46 (-1.88 %)
$ 2.92
$ 2.81
$ 2.80 x 250
$ 2.98 x 10
$ 2.81 - $ 2.93
$ 0.40 - $ 5.48
53,581
na
50.77M
$ 0.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-17-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 08-14-2023 06-30-2023 10-Q
9 05-15-2023 03-31-2023 10-Q
10 03-31-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-15-2022 06-30-2022 10-Q
13 05-16-2022 03-31-2022 10-Q
14 03-31-2022 12-31-2021 10-K
15 11-15-2021 09-30-2021 10-Q
16 08-11-2021 06-30-2021 10-Q
17 05-10-2021 03-31-2021 10-Q
18 03-16-2021 12-31-2020 10-K
19 11-17-2020 09-30-2020 10-Q
20 08-14-2020 06-30-2020 10-Q
21 06-30-2020 03-31-2020 10-Q
22 05-15-2020 12-31-2019 10-K
23 11-18-2019 09-30-2019 10-Q
24 08-09-2019 06-30-2019 10-Q
25 05-28-2019 03-31-2019 10-Q
26 04-15-2019 12-31-2018 10-K
27 11-14-2018 09-30-2018 10-Q
28 08-20-2018 06-30-2018 10-Q
29 05-15-2018 03-31-2018 10-Q
30 01-16-2018 09-30-2017 10-K
31 08-21-2017 06-30-2017 10-Q
32 05-22-2017 03-31-2017 10-Q
33 02-21-2017 12-31-2016 10-Q
34 01-12-2017 09-30-2016 10-K
35 08-15-2016 06-30-2016 10-Q
36 05-16-2016 03-31-2016 10-Q
37 02-23-2016 12-31-2015 10-Q
38 11-27-2015 09-30-2015 10-K
39 08-19-2015 06-30-2015 10-Q
40 05-15-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abvc-biopharma-q2-eps-013-down-from-009-yoy

ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(...

 abvc-biopharma-secures-japanese-patent-for-its-natural-mdd-treatment-candidate-abv-1504

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central...

 abvc-biopharma-determined-that-it-has-a-material-weakness-in-its-internal-controls-over-financial-reporting-concluded-that-financial-statements-for-fy-ended-dec-31-2023-should-no-longer-be-relied-upon-due-to-errors-in-financial-statements

- SEC Filing

 abvc-biopharmas-leeds-chow-resigns-as-cfo-ceo-uttam-patil-to-serve-as-interim-cfo

- SEC Filing

 abvc-biopharma-seeks-to-revolutionize-mental-health-treatment-with-a-safe-prozac-alternative-boasting-a-madrs-score-reduction-of--1321-from-baseline-over-6-weeks-with-a-placebo-subtracted-difference-of--41

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmolog...

 abvc-biopharma-reveals-receipt-of-200k-cash-payment-from-oncox-biopharma-as-part-of-its-strategic-licensing-agreement-for-certain-oncology-related-products

This payment marks the first installment of $5 million in potential licensing fees from OncoX.With this payment, the total accu...

 abvc-biopharma-receives-50000-in-incremental-licensing-fees

With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner&...

 abvc-biopharma-got-written-notification-from-nasdaq-indicating-co-regained-compliance-with-listing-rules-5635a1-and-5635a2

- SEC Filing

 abvc-biopharma--biolite-entered-into-definitive-agreement-with-oncox-biopharma-to-collaborate-on-combination-therapy-abvc--unit-are-eligible-to-receive-aggregate-license-fee-of-125m-in-form-of-cash-or-shares-of-oncox-securities-under-terms-of-deal-abvc-grants-oncox-exclusive-rights-for-one-of-abvcs-4-products-in-its-oncology-pipeline

- SEC Filing 

 abvc-biopharma-collaboration-between-abvc-and-oncox-biopharma-abvc-expecting-aggregate-income-of-1375m-and-royalties-of-up-to-1250m-grants-oncox-exclusive-rights-for-one-of-abvcs-four-products-in-its-oncology-pipeline-to-develop-manufacture-commercialize-blex-404

https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION